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ABSTRACT
Objectives: Osteoarthritis (OA) is a joint disease common in the elderly. There is a prior functional
evidence for different matrix metalloproteinases (MMPs), such as MMP8 and MMP9, having a role
in the breakdown of cartilage extracellular matrix in OA. Thus, we analyzed whether the common
genetic variants of MMP8 and MMP9 contribute to the risk of OA. Materials and methods: In total,
13 common tagging single-nucleotide polymorphisms (SNPs) were studied in a discovery knee OA
cohort of 185 cases and 895 controls. For validation, two knee OA replication cohorts and two
hand OA replication cohorts were studied (altogether 1369 OA cases, 4445 controls in the five
cohorts). The χ2 test for individual study cohorts and Cochran–Mantel–Haenszel test for combined
meta-analysis were calculated using Plink. Results: The rs1940475 SNP in MMP8 showed sugges-
tive association in the discovery cohort (OR = 0.721, 95% CI 0.575–0.906; p = 0.005). Other knee
and hand OA replication study cohorts showed similar trend for the predisposing allele without
reaching statistical significance in independent replication cohorts nor in their meta-analysis (p >
0.05). Meta-analysis of all five hand and knee OA study cohorts yielded a p-value of 0.027 (OR =
0.904, 95% CI 0.826–0.989). Conclusions: Initial analysis of the MMP8 gene showed suggestive
association between rs1940475 and knee OA, but the finding did not replicate in other study
cohorts, even though the trend for predisposing allele was similar in all five cohorts. MMP-8 is a
good biological candidate for OA, but our study did not find common variants with significant
association in the gene.
ARTICLE HISTORY
Received 2 June 2015
Revised 16 September 2015
Accepted 18 September
2015
Published online 13 January
2016
KEYWORDS
Association; gene; matrix
metalloproteinase 8;
osteoarthritis
Introduction
The osteoarthritis (OA)-predisposing genes identified
so far have been able to explain only little of the
39–65% heritability of this joint-destructing disease
(1,2). The disease affects the bone, cartilage, and
synovium, inflammatory factors playing a role in the
process. One characteristic feature of the cartilage
degeneration in OA is the breakdown of extracellular
matrix by different matrix metalloproteinases (MMPs)
(3). Many studies have shown the role of MMPs in OA,
MMP-1 and MMP-13 being some of the most
relevant in OA (4,5). Tetlow et al. (6) showed that the
expression of different cartilage-breaking MMPs of
chondrocytes was greater in the superficial zone of
cartilage where degenerative changes were more
common compared to the deeper zones.
The type I, II, and III collagen-breaking MMP-8
seems to play some role in OA, even though it cannot
be considered as the main factor in OA. The level of
MMP-8 in the cartilage has shown to be higher in OA
patients than in controls (p = 0.0135) (7) and the
expression of MMP-8 is significantly increased in the
joints of mice that have collagen-induced arthritis
compared to healthy mice (8). Besides type II collagen,
another component of the cartilage is the type IX
collagen stabilizing the collagen network. MMP-9 can
break down this collagen and other components in the
cartilage and has been shown to be differentially
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expressed in OA compared to healthy cartilage.
For example, MMP-9 was upregulated in human OA
cartilage and synovium compared to controls (7).
Similarly, Flannelly et al. (9) found the levels of MMP-
9 to be higher in the tibial articular chondrocytes of
STR/ort mice that spontaneously generate OA than the
control CBA mice, and MMP-9 was immunolocalized in
growth cartilage. Also, Freemont et al. (10) have shown
that the MMP9 gene is upregulated in deep cartilage
layers of human knee OA samples in early disease stages.
Our aim was to investigate if there were common
allelic variants in MMP8 and MMP9 genes that associate
with knee OA. We hypothesized that the studied
variants, or variants in high correlation with them,
might have an impact on the structure or activity of
the enzymes and thus affect their function by protecting
or predisposing the carriers to OA.
Study subjects
The study was approved by the ethics committee of the
Helsinki metropolitan hospital region in Finland
(11,12) and Ethical Committee for Clinical Research
of Galicia in Spain. All individuals gave their written
informed consent. We analyzed three knee OA study
cohorts and two hand OA cohorts (Table 1).
Finnish knee OA discovery cohort
Our knee OA discovery cohort was composed of 185
knee OA cases of Finnish origin. Of these, 110 were
radiologically verified severe (at least grade 3/4 in
Kellgren and Lawrance classification), bilateral knee
OA cases. Their symptoms were severe enough to
fulfill the criteria for knee arthroplasty having pain
and walking disability. The symptoms began at a
mean age of 52 years (SD 12 years), and the mean age
at first arthroplasty was 67 years (SD 8). Study subjects
that suffered from RA or had previous severe knee
trauma were excluded. Altogether, 28 of the knee OA
patients also had physician-diagnosed hand OA. For
details, see (11). The other half of the discovery cohort
was selected from the population-based Finnish Health
2000 cohort (n = 8028). Genome-wide SNP array data
were available for 2118 cohort members, who had been
ascertained for a nested matched case–control study of
metabolic syndrome (the Genmets study) (13). Seventy-
five (75) of the 2118 individuals were over the age of
50 years and had a clinician-diagnosed probable or
definite knee OA and were included in the discovery
knee OA case group. In total, 895 Genmets study
individuals were over 50 years of age and did not
have clinician-diagnosed probable or definite knee or
hip OA and were used as controls. Individuals suffering
from RA or having an unknown RA status were
excluded from the case and control groups (n = 28).
Knee OA replication cohorts
For validation of the initial association, we analyzed
one SNP in two independent knee OA replication
cohorts. The first replication cohort consisted of 302
clinician-diagnosed knee OA cases and 1700 controls
from the Health 2000 study that were not genotyped
with the genome-wide SNP array. The cases were
selected using the same clinician-diagnosed criteria as
in the Finnish knee OA discovery cohort.
The second knee OA replication cohort consisted
of 254 knee OA cases and 449 controls of Spanish
ancestry. Cases were undergoing knee joint replace-
ment and were included if a rheumatologist considered
them to suffer from severe primary OA. Exclusion
criteria were inflammatory, infectious, traumatic or
congenital joint pathology, and lesions due to crystal
deposition or osteonecrosis. Controls were recruited
among subjects older than 55 years of age undergoing
preoperative work-up for elective surgeries other
than joint surgery and who did not show clinical
manifestations of OA.
Hand OA replication cohorts
For verification of the finding in another OA type, we
used two Finnish hand OA study groups. The first hand
Table 1. Study cohorts.
Study cohort Cases Controls
Finnish knee OA discovery cohort 185 895
Radiological* 110 0
Clinical 75 895
Females (%) 72.4 53.6
Finnish knee OA replication cohort 302 1700
Clinical 302 1700
Females (%) 66.2 64.6
Spanish knee OA replication cohort 254 449
Total knee replacement surgery 254 449
Females (%) 80.3 35.4
Knee OA in total 741 3040
Finnish hand OA replication cohort 1* 132 435
Radiological 104 0
Clinical** 28 435
Females (%) 81.8 36.3
Finnish hand OA replication cohort 2 524 970
Visual grading 524 970
Females (%) 67.7 49.5
Hand OA in total 656 1405
All in total 1369 4445
*Family-based study cohort in which 84 individuals are unrelated. Study
cohort includes also additional 21 unaffected family member. **In total,
28 study subjects were included in the Finnish knee OA discovery cohort
(radiological) and Finnish hand OA replication cohort 1 (clinical). The
study subjects were included in the knee OA study group and excluded
from hand OA study group in the combined knee and hand OA meta-
analysis, and also excluded from the hand OA study group in the
independent replication meta-analysis.
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OA replication cohort consisted of 132 Finnish
radiologically verified severe (at least grade 3/4 in
Kellgren and Lawrance classification), bilateral familial
hand OA patients and 21 unaffected family members.
Eighty-four (84) of the cases were unrelated. Subjects
with rheumatoid arthritis (RA) were excluded (11,14).
Of these, 28 individuals were also included in the
Finnish knee OA discovery cohort. (The 28 study
subjects were included in knee OA study group and
excluded from hand OA study group in the combined
hand and knee OA meta-analysis utilizing all five
study cohorts. Also, the 28 study subjects were excluded
from the independent replication meta-analysis with
four replication cohorts.) The controls (n = 435) were
selected from the Finnish twin cohort (males aged
35–70). One twin from a twin pair not having a clin-
ician-diagnosed OA was included in the control
group (11).
The second hand OA replication cohort was part of
Finnish Helsinki Birth Cohort Study (15). All study
subjects were over 56 years of age. Hand joints of the
study subjects were visually evaluated and individuals
with Heberden’s nodes in at least one DIP joint were
graded as affected (n = 524). Individuals graded as
healthy (n = 970) had visually healthy and symptomless
finger joints.
Methods
Genotyping
Genotyping of the finnish knee OA discovery study
cohort
MMP8 and MMP9 genes were selected to a tag SNP
association study based on their suggestive functional
significance in OA and an initial candidate gene analy-
sis of 25 genes (99 SNPs) (12) in a subset of the
discovery knee OA study set (data not shown). Tag
SNPs of the MMP8 and MMP9 genes also present in
the genome-wide Illumina HumanHap 610 chip were
selected (Illumina, Inc., San Diego, CA).
In total, 13 SNPs in MMP8 and MMP9 were geno-
typed in the entire Finnish knee OA discovery cohort
using two methods. The Sequenom iPLEX Gold assay
on the MassARRAY® Platform (Sequenom Inc., San
Diego, CA) was used according to the manufacturer’s
instructions for genotyping of 110 cases. SNP assays
were designed using the MassARRAY™ Assay Design
program (Sequenom Inc.) that designed PCR and
extension primers and arranged the SNPs in two multi-
plexes. Each SNP multiplex was validated by genotyp-
ing 93 trio samples (i.e., 31 families with two parents
and a child). The genotyping was done in 384-well
plates with 35 duplicate samples and 8 non-template
wells. The genotype data were assessed using the
Sequenom Typer Analyzer program with quality con-
trol criteria of at least half of the assays in a sample well
performing successfully, visually clear genotype cluster-
ing, at least 90% success rate for an assay, and 90%
success rate for a sample. If the genotype calling,
Mendelian inheritance test using the Pedcheck 1.1 pro-
gram (16), duplicate samples, or non-template wells
revealed unreliable SNP assay, the SNP was excluded
from the study.
We also had data available for the selected SNPs
from the Illumina HumanHap 610 whole-genome
SNP chip (Illumina, Inc.) for 75 cases and 895 controls
of the Genmets study (13) that were part of the Finnish
knee OA discovery cohort. Markers with genotyping
success rate of less than 95%, minor allele frequency
less than 1%, and Hardy–Weinberg equilibrium less
than 1 × 10−6 were excluded. Of the 2440 individuals
with the genome-wide data, we excluded those with
genotyping success rate less than 95%, high genomic
heterozygosity indicating putative sample contamina-
tion, gender discrepancies, or close relatedness with
another individual (π ̂ > 0.1) (n = 322). Altogether,
2118 individuals and 555,388 markers passed the qual-
ity control.
Genotyping of the knee OA replication cohorts
One SNP was genotyped in replication cohorts. The
Finnish knee OA replication study cohort was geno-
typed using the Sequenom system (Sequenom Inc.) as
described above.
Spanish knee OA replication study cohort was gen-
otyped using single-base extension reactions with the
SNaPshot Multiplex Kit (Applied Biosystems, Foster
City, CA, USA). Genotypes were obtained in the Abi-
Prism 3130xl Genetic Analyzer (Applied Biosystems)
with a 98.4% call rate.
Genotyping of the hand OA replication cohorts
Finnish hand OA replication cohort 1 was genotyped
using homogeneous MassEXTEND™ (hME) technology
by the Sequenom MassARRAY® platform (Sequenom
Inc.) as recommended by the manufacturer with addi-
tional quality control. Genotyping assays were designed
using the SpectroDESIGNER 1.3 program (Sequenom
Inc.) that designed PCR and extension primers and
arranged the SNPs in to multiplexes of one to five
SNPs. Each SNP multiplex was validated by genotyping
81 trio samples (i.e., 27 families with two parents and a
child) to control for Mendelian incompatibilities using
Pedcheck 1.1 program (16). The genotyping was done
in 384-well plates with eight duplicate samples and
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eight non-template wells. If either automated or man-
ual genotype calling using the Sequenom Typer
Analyzer program (Sequenom Inc.), Mendelian inheri-
tance test, duplicate samples, or non-template wells
revealed unreliable SNP assay, the SNP was excluded
from the study. Further, only SNPs with call rate of
over 90% were included.
Finnish hand OA replication cohort 2 was genotyped
using the Illumina HumanHap 610 chip (Illumina, Inc.)
as described above.
Data analyses
First, the Haploview program (17) was used to measure
the linkage disequilibrium (LD) structure of the studied
genes in the discovery set controls as r2 measure.
Hardy–Weinberg equilibrium for each SNP was
assessed using Haploview (17). The SNPSpd method
was used to assess the p-value threshold for 5% signifi-
cance, considering the LD structure of the studied
SNPs. This method utilizes the LD structure of the
studied region, and markers in strong LD are consid-
ered as one test (http://gump.qimr.edu.au/general/
daleN/SNPSpD/) (18,19).
For unrelated individuals, the χ2 association analysis,
meta-analysis (Cochran–Mantel–Haenszel), and het-
erogeneity between study cohorts in the meta-analysis
(I2 heterogeneity index, Cochran Q) were calculated
using the Plink program v1.07 (20) (http://pngu.mgh.
harvard.edu/purcell/plink/). For the combined family
and case–control setting of hand OA association ana-
lysis (Finnish hand OA replication cohort 1), the
Pseudomarker program was used. The Pseudomarker
program utilizes combined data of families and single-
tons and calculates the association with the presence of
linkage (21,22).
Results
Altogether, 13 SNPs were studied in the Finnish knee
OA discovery study cohort. The SNPs covered 62%
of the common variation in the MMP8 gene (±5 kb)
and 67% in the MMP9 gene (±5 kb) according to the
Tagger program (http://www.broadinstitute.org/mpg/
tagger/) (23). Maximum r2 correlation of 80%
between the markers and allele frequency threshold
of 10% was used. Reference population was HapMap
CEU: Utah residents with ancestry from northern
and western Europe; phased HapMap Release 21
(24). The LD structures of the studied genes in
discovery cohort controls are shown in Figure 1.
Based on the SNPSpD method (18,19) the level of
5% significance was reached with a p-value of 0.0057
corresponding to the effective number of nine SNPs.
The most significant association was further analyzed
in independent replication cohorts of knee OA and
hand OA.
Two SNPs, rs1940475 and rs3765620, showed an
association with knee OA in the Finnish knee OA
discovery cohort (p = 0.005 and p = 0.004, respec-
tively) (Table 2). The two SNPs were in LD with each
other (r2 82%). Due to the high correlation between
the SNPs, only the rs1940475 marker was further
analyzed in two independent knee OA and in two
independent hand OA replication cohorts. In all four
study cohorts, the allele frequency difference between
cases and controls was in the same direction as
observed in the initial discovery study set of 185
cases and 895 controls. However, the initial finding
did not replicate statistically significantly in any of the
four independent replication study sets of knee and
hand OA (p > 0.05) nor in a meta-analysis combing
the four replication study sets (p = 0.236). When
including the discovery study set in the meta-analysis,
Figure 1. The LD structure of the studied genes in the controls. The LD structure of the MMP9 and MMP8 genes is presented as a
measure of r2. Stronger color indicates higher level of pairwise LD between each SNP pair, black color indicating 100% LD.
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p-value of 0.027 was obtained (Table 3; Figure 2).
The I2 heterogeneity index was 34.9 (1–100) and the
p-value for Cochran Q statistic was 0.189, indicating
that there was no significant heterogeneity among the
five study populations.
Discussion
Altogether, 13 SNPs in the MMP8 and MMP9 genes
were studied in knee OA, and a statistically significant
association with two SNPs (rs1940475 and rs3765620)
in high LD with each other inMMP8 was observed (p <
0.0057). One of the SNPs rs1940475 was further
analyzed in four independent replication cohorts, but
the finding did not replicate in any of the knee and
hand OA cohorts independently nor in a combined
meta-analysis of the independent cohorts, although
the trend for the C-allele being more common in OA
cases was similar in all five study cohorts.
The power to detect the level of association seen for
rs1940475 was 50% in the Finnish knee OA discovery
cohort. Roughly 500 cases would have been needed
for 80% power of detecting the association with 5%
confidence level corresponding 95% CI. When assum-
ing similar allele frequencies for the follow-up cohorts
as in the discovery cohort, the power to detect associa-
tion in the individual follow-up cohorts varied between
30 and 80%. The power was 99.9% in the meta-analysis
of the four independent replication cohorts. However,
the effect size in the Finnish knee OA discovery
cohort has probably been overestimated (25). This is
in accordance with previous publications showing that
Table 2. The results of association analysis in the Finnish knee OA discovery cohort.
Chr Gene SNP Location Al. Freq ctrls Freq cases χ2 p-value OR L95 U95
20 MMP9 rs3933239 44062075 A 0.465 0.473 0.803 1.029 0.821 1.290
20 MMP9 rs4810482 44067957 C 0.396 0.398 0.936 1.009 0.802 1.271
20 MMP9 rs3918278 44069061 A 0.050 0.038 0.328 0.751 0.423 1.335
20 MMP9 rs17576 44073632 G 0.390 0.392 0.945 1.008 0.799 1.272
20 MMP9 rs3918261 44076999 G 0.169 0.175 0.792 1.041 0.772 1.403
11 MMP8 rs12274992 102084124 T 0.051 0.074 0.088 1.470 0.942 2.293
11 MMP8 rs3740938 102092272 A 0.074 0.068 0.688 0.913 0.587 1.422
11 MMP8 rs2012390 102095987 C 0.205 0.186 0.417 0.888 0.666 1.183
11 MMP8 rs1940475a 102098458 T 0.493 0.413 0.005 0.721 0.575 0.906
11 MMP8 rs7123682 102099237 C 0.129 0.159 0.132 1.271 0.930 1.738
11 MMP8 rs3765620b 102100702 G 0.446 0.363 0.004 0.710 0.562 0.895
11 MMP8 rs7943404 102103785 G 0.378 0.431 0.060 1.245 0.990 1.565
11 MMP8 rs10895354 102104264 C 0.129 0.159 0.125 1.277 0.934 1.746
Chr = chromosome; Location = genomic location in base pairs; Al. = minor allele for which the ORs are given; Freq ctrls = allele frequency in controls; Freq
cases = allele frequency in cases; OR = odds ratio; L95 and U95 = 95% confidence interval; aGenotyped also in other study cohorts (Table 3); bp-value in the
Finnish hand OA replication cohort 2 = 0.741 based on the GWAS data; OR = 0.975, 95% CI 0.837–1.135.
Table 3. Meta-analysis of rs1940475.
Freq ctrls Freq cases χ2 p-value OR L95 U95
Finnish knee OA discovery cohort 0.493 0.413 0.005 0.721 0.575 0.906
Finnish knee OA replication cohort 0.473 0.454 0.371 0.924 0.776 1.099
Spanish knee OA replication cohort 0.462 0.461 0.966 0.995 0.800 1.239
Knee OA META 0.039 0.884 0.787 0.994
Finnish hand OA replication cohort 1 0.484 0.428 0.187a 0.798 0.571 1.116
Finnish hand OA replication cohort 2b 0.474 0.465 0.639 0.965 0.830 1.121
Hand OA META 0.332 0.934 0.814 1.072
Independent replication OA METAc 0.236 0.943 0.855 1.039
All cohorts OA META 0.027 0.904 0.826 0.989
aOnly unrelated individuals, 84 cases and 435 controls, were included in the χ2 analysis. In the family-based association test with 132 affected, 21 unaffected
and 435 controls, the p-value was 0.192 using Pseudomarker. The p-value for linkage was 0.0399 in the Pseudomarker analysis; bincluding the 28 clinical
hand OA cases that are also part of the Finnish knee OA discovery cohort; cexcluding the 28 clinical hand OA cases that are also part of the Finnish knee OA
discovery cohort.
Figure 2. Forest plot of meta-analysis for the T allele of the
1940475 SNP. Odds ratios and 95% confidence intervals. The
sizes of the dots are in proportion with the amount of cases in
the study cohort. Finnish hand OA replication cohort 1 includes
the 28 clinical hand OA cases that are also part of the Finnish knee
OA discovery cohort; independent replication meta-analysis
excludes the 28 clinical hand OA cases that are also part of the
Finnish knee OA discovery cohort.
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effect sizes typically seen in complex disease mapping
require thousands of study samples for detection of
association or for excluding the role of a single variant
in a disease (26).
Both originally associated SNPs are non-synonymous.
The rs1940475 changes the positively charged lysine to
negatively charged glutamic acid (Lys87 to Glu) and
the rs3765620 changes the polar threonine to nonpolar
isoleucine (Thr32 to Ile). Both amino acid changes
were predicted to be tolerated according to the SIFT
program (27,28).
We did not observe significant evidence of
association to the studied common variants in the
MMP8 gene. There is some functional evidence for
the role of MMP-8 in OA, making it an interesting
study target, even though it is not the main MMP
released in OA. MMP-8 can cleave the major collagen
of the cartilage, collagen type II, and also collagens
type I, III, other ECM compounds, and non-structural
molecules as well and affect neutrophil migration (29).
MMP-8 is expressed by neutrophils (30), chondrocytes
(31–33) especially mature chondrocytes (34), and
chondrocytes following a proinflammatory stimulus
(35). Billinghurst et al. (3) showed that the increased
expression of MMP-8 is associated with increased
cleavage of type II collagen in human osteoarthritic
cartilage. The MMP-8 mRNA has been shown to be
absent from normal cartilage but present in naturally
occurring (7,36,37) and in IL-1β-induced OA cartilage
similarly to the MMP-8 protein (6,7). MMP-8 mRNA
levels were higher in chondrocytes obtained from the
surrounding areas of OA lesion when compared with
those seen in chondrocytes from other areas of the
cartilage (38). Also the MMP-8 protein levels were
higher in the superficial zone of OA cartilage and
they were especially associated with areas suffering
from matrix depletion, fibrillations, chondrocyte
clusters, and loss of metachromasia. Protein levels
were lower or absent from the deep zone and showed
normal hyaline cartilage and chondrocyte morphology
(6). Moreover, MMP-8 inhibition has shown promising
results. Tetracycline (39), doxycycline (38), and Ro
32-3555 (an orally active collagenase selective inhibitor,
Trocade®) (40) seem to inhibit neutrophil MMP-8
activity in vitro. Doxycycline has been tested success-
fully in reactive arthritis patients (41) and also Ro
32-3555 leads to significant protection of cartilage,
inhibition of osteophyte formation, and reduction in
joint space narrowing in the STR/Ort mouse model of
OA (42).
Previous genome-wide association studies (GWASs)
have revealed genome-wide significant (p < 5 × 10−8)
findings in OA. Many of the findings are performed in
large study samples, but as is typical in complex diseases,
the effect sizes have been small and fine-mapping
is required to identify the causal variants. The
previous GWAS findings in OA include extracellular
signaling molecule GDF5 (growth differentiation fac-
tor 5) (43,44), DVWA (von Willebrand factor) (45),
7q22 region with GPR22 (G-protein coupled receptor
22) (46,47), a skeletal and pain-related gene MCF2L
(MCF.2 cell line derived transforming sequence-like,
encoding the rho-specific guanine nucleotide exchange
factor) (48), the FTO gene (fat mass and obesity asso-
ciated) (48), membrane protein ASTN2 (astrotactin 2)
(49), a wnt signaling gene DOT1L (DOT1-like, histone
H3 methyltransferase) (50), nuclear receptor activator
gene NCOA3 (nuclear receptor coactivator 3) (51), and
HLA class II/III region (52).
The arcOGEN Consortium (49) published the details
of their top 129 SNP findings (p < 10−5) in OA with
7410 OA cases and 11009 controls, but the MMP8 and
MMP9 genes were not among the published regions
nor in the genome-wide significant regions of other
GWASs mentioned above. However, the MMP9 gene
is located in the chromosome 20q13.12 locus together
with the NCOA3 gene associating with hip OA in the
previous GWAS (p = 7.9 × 10−9, OR = 1.28, 95% CI
1.18–1.39, 11,277 hip OA cases, 78,000 participants)
(51), but the two genes are more than 1 Mb apart,
thus the negative finding of the current study is likely
an independent signal from the association finding of
the hip OA GWAS study in another study population.
Conclusions
A suggestive association in a discovery knee OA study
cohort was observed with two common SNPs,
rs1940475 and rs3765620, in the MMP8 gene, which
has previously been shown to have a functional role
in OA. However, the finding was not replicated with
statistical significance in follow-up analyses of hand
and knee OA.
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